Schedule of Segment Information Related to Statement of Operations (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||||
| Segment Reporting [Line Items] | ||||||||
| Revenue | $ 86,346 | $ 129,904 | $ 222,665 | $ 689,680 | ||||
| Operating Expenses: | ||||||||
| Credit loss expense | 150,000 | 124,253 | ||||||
| Operating expenses | 627,216 | 775,922 | 1,148,598 | 1,412,398 | ||||
| Research and Development Expenses: | ||||||||
| Research and development expenses | 128,884 | 169,086 | 274,234 | 331,963 | ||||
| Operating loss | (669,754) | (815,104) | (1,200,167) | (1,054,681) | ||||
| Single Reportable Segment [Member] | ||||||||
| Segment Reporting [Line Items] | ||||||||
| Revenue | 86,346 | 129,904 | 222,665 | 689,680 | ||||
| Operating Expenses: | ||||||||
| Employee compensation | 201,731 | 312,560 | 460,885 | 599,072 | ||||
| Professional fees | 55,404 | 44,757 | 162,204 | 132,657 | ||||
| Directors fees and expenses | 154 | 107,107 | 154 | 227,107 | ||||
| Marketing and investor relations | 35,209 | 48,756 | 56,465 | 79,002 | ||||
| Insurance | [1] | 31,243 | 45,355 | 67,359 | 91,544 | |||
| Occupancy costs | 19,998 | 20,615 | 39,664 | 42,132 | ||||
| Credit loss expense | 150,000 | 124,253 | 150,000 | 124,253 | ||||
| Patent costs | 21,957 | 15,313 | 54,532 | 27,117 | ||||
| Stock listing fees | 18,125 | 17,500 | 36,250 | 35,000 | ||||
| Legal fees | 76,675 | 1,070 | 96,224 | 1,070 | ||||
| Depreciation and amortization | 145 | 2,864 | 289 | 5,723 | ||||
| Other operating expenses | [2] | 16,575 | 35,772 | 24,572 | 47,721 | |||
| Operating expenses | 627,216 | 775,922 | 1,148,598 | 1,412,398 | ||||
| Research and Development Expenses: | ||||||||
| Employee compensation | 34,167 | 43,280 | 81,588 | 90,643 | ||||
| Insurance | [1] | 30,612 | 44,425 | 65,848 | 89,635 | |||
| Occupancy costs | 59,993 | 63,252 | 118,989 | 127,796 | ||||
| Depreciation and amortization | 173 | 223 | 342 | 443 | ||||
| Other research and development costs | [2] | 3,939 | 17,906 | 7,467 | 23,446 | |||
| Research and development expenses | 128,884 | 169,086 | 274,234 | 331,963 | ||||
| Operating loss | $ (669,754) | $ (815,104) | $ (1,200,167) | $ (1,054,681) | ||||
| ||||||||
| X | ||||||||||
- Definition The amount of expense in the period for insurance. No definition available.
|
| X | ||||||||||
- Definition The amount of expense in the period for patent costs. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development depreciation and amortization. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development employee compensation. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development insurance. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development occupancy costs. No definition available.
|
| X | ||||||||||
- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for employee benefit and equity-based compensation. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of expense during the period for floor brokerage fees paid to other broker-dealers to execute trades on their behalf, stock exchange fees, order flow fees, and clearance fees. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for service provided by entity's director. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of net occupancy expense that may include items, such as depreciation of facilities and equipment, lease expenses, property taxes and property and casualty insurance expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense (reversal of expense) for expected credit loss on accounts receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|